866-997-4948(US-Canada Toll Free)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 257 Pages

This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 9
Therapeutics Development 10
Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 10
Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis 11
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 12
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 16
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 22
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 25
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 26
Bristol-Myers Squibb Company 26
Daiichi Sankyo Company, Limited 27
Merck & Co., Inc. 28
Gamida Cell Ltd. 29
BioLineRx, Ltd. 30
Nanotherapeutics, Inc. 31
Bio-Path Holdings, Inc. 32
Novartis AG 33
Pfizer Inc. 34
Sun Pharmaceutical Industries Limited 35
Celgene Corporation 36
Incyte Corporation 37
Ariad Pharmaceuticals, Inc. 38
JW Pharmaceutical Corporation 39
Ilyang Pharmaceutical Co., Ltd 40
Jiangsu Hengrui Medicine Co., Ltd. 41
Threshold Pharmaceuticals, Inc. 42
Synta Pharmaceuticals Corp. 43
Natco Pharma Limited 44
SymBio Pharmaceuticals Limited 45
Nerviano Medical Sciences S.r.l. 46
Deciphera Pharmaceuticals, LLC 47
Stemline Therapeutics, Inc. 48
Onconova Therapeutics, Inc. 49
KaloBios Pharmaceuticals, Inc. 50
AB Science 51
Kinex Pharmaceuticals, LLC 52
EpiZyme, Inc. 53
Targa Therapeutics Corp. 54
Otsuka Holdings Co., Ltd. 55
EirGen Pharma Ltd. 56
BerGenBio AS 57
Karyopharm Therapeutics, Inc. 58
Xiamen Amoytop Biotech Co., Ltd. 59
Hanmi Pharmaceuticals, Co. Ltd. 60
Cantargia AB 61
AbbVie Inc. 62
Biogenomics 63
Galileo Research s.r.l. 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Target 66
Assessment by Mechanism of Action 70
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 79
ponatinib - Drug Profile 79
StemEx - Drug Profile 81
radotinib - Drug Profile 83
ponatinib - Drug Profile 85
BMS-833923 - Drug Profile 87
Triapine - Drug Profile 89
danusertib - Drug Profile 91
Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - Drug Profile 93
NRC-AN-019 - Drug Profile 94
TALL-104 - Drug Profile 96
HHGV-678 - Drug Profile 98
WT1 DNA Vaccine - Drug Profile 99
bosutinib - Drug Profile 100
lonafarnib - Drug Profile 102
ganetespib - Drug Profile 104
ruxolitinib phosphate - Drug Profile 108
SL-401 - Drug Profile 112
KB-004 - Drug Profile 114
WT-1 TCR Gene Therapy - Drug Profile 116
PRI-724 - Drug Profile 117
Minor Histocompatibility Antigen - Drug Profile 119
azacitidine - Drug Profile 120
TH-302 - Drug Profile 123
GM-K562 Cell Vaccine - Drug Profile 130
HuM-195/rGel - Drug Profile 132
ciclopirox olamine - Drug Profile 133
exatecan mesylate - Drug Profile 134
Bcr-abl Multipeptide Vaccine - Drug Profile 136
erismodegib - Drug Profile 137
BP-100-1.01 - Drug Profile 139
rebastinib tosylate - Drug Profile 141
ilorasertib - Drug Profile 143
OPB-51602 - Drug Profile 145
KX-01 - Drug Profile 146
CWP-232291 - Drug Profile 148
KPT-330 - Drug Profile 150
EPZ-5676 - Drug Profile 152
SL-501 - Drug Profile 153
ON-044580 - Drug Profile 154
SyB-0702 - Drug Profile 155
HM-95091 - Drug Profile 156
MRx-102 - Drug Profile 157
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 159
BGB-324 - Drug Profile 161
D-12-PGJ-3 - Drug Profile 162
Lenaldekar - Drug Profile 163
Sun-K706 - Drug Profile 164
BL-8040 - Drug Profile 165
interferon alfa-2a biosimilar - Drug Profile 167
ADAR1 Inhibitors - Drug Profile 168
OP-449 - Drug Profile 169
interferon alfa-2b biosimilar - Drug Profile 171
DP-00605 - Drug Profile 172
D-824 - Drug Profile 173
interferon alfa-2a - Drug Profile 174
ON-012380 - Drug Profile 175
ON-044590 - Drug Profile 176
Drug For Chronic Myeloid Leukemia - Drug Profile 177
Drugs Targeting ABL - Drug Profile 178
TR-120 - Drug Profile 179
NOV-120501 - Drug Profile 180
Small Molecule to Inhibit BCR-Abl/LYN for Chronic Myelocytic Leukemia - Drug Profile 181
DR4 Specific Mutant TRAIL Proteins - Drug Profile 182
Combretastatin Analogues - Drug Profile 183
Small Molecules to Inhibit BRCA2/Rad51 Interaction - Drug Profile 184
Eir-108 - Drug Profile 185
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 186
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 236
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 237
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 238
Featured News & Press Releases 238

Appendix 251
Methodology 251
Coverage 251
Secondary Research 251
Primary Research 251
Expert Panel Validation 251
Contact Us 252
Disclaimer 252

List of Table


Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2014 15
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Late Stage Development, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Comparative Analysis by Unknown Stage Development, H1 2014 26
Products under Development by Companies, H1 2014 27
Products under Development by Companies, H1 2014 (Contd..1) 28
Products under Development by Companies, H1 2014 (Contd..2) 29
Products under Investigation by Universities/Institutes, H1 2014 30
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2014 31
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 32
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Merck & Co., Inc., H1 2014 33
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd., H1 2014 34
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx, Ltd., H1 2014 35
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Nanotherapeutics, Inc., H1 2014 36
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2014 37
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2014 38
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc., H1 2014 39
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 40
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corporation, H1 2014 41
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corporation, H1 2014 42
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 43
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corporation, H1 2014 44
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2014 45
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 46
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 47
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 48
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Limited, H1 2014 49
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SymBio Pharmaceuticals Limited, H1 2014 50
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 51
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 52
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2014 53
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2014 54
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 55
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AB Science, H1 2014 56
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Kinex Pharmaceuticals, LLC, H1 2014 57
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme, Inc., H1 2014 58
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Targa Therapeutics Corp., H1 2014 59
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 60
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EirGen Pharma Ltd., H1 2014 61
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BerGenBio AS, H1 2014 62
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 63
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Xiamen Amoytop Biotech Co., Ltd., H1 2014 64
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 65
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H1 2014 66
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc., H1 2014 67
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics, H1 2014 68
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galileo Research s.r.l., H1 2014 69
Assessment by Monotherapy Products, H1 2014 70
Number of Products by Stage and Target, H1 2014 73
Number of Products by Stage and Mechanism of Action, H1 2014 77
Number of Products by Stage and Route of Administration, H1 2014 80
Number of Products by Stage and Molecule Type, H1 2014 83
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Recent Pipeline Updates, H1 2014 191
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2014 241
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2014 242

List of Chart


Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2014 15
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Late Stage Development, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 70
Number of Products by Top 10 Target, H1 2014 71
Number of Products by Stage and Top 10 Target, H1 2014 72
Number of Products by Top 10 Mechanism of Action, H1 2014 75
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 76
Number of Products by Top 10 Route of Administration, H1 2014 79
Number of Products by Stage and Top 10 Route of Administration, H1 2014 80
Number of Products by Top 10 Molecule Type, H1 2014 81
Number of Products by Stage and Top 10 Molecule Type, H1 2014 82

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *